You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GSK2857916, Pembrolizumab, Multiple Myeloma, RP2D

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed and/or Refractory Multiple Myeloma Trial in Canada (GSK2857916 with Pomalidomide and Dexamethasone)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • GSK2857916 with Pomalidomide and Dexamethasone
  • Edmonton, Alberta, Canada
  • +8 more
Feb 14, 2022

Multiple Myeloma Trial (Bela, Belamaf, Lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jan 27, 2023

Myeloma Trial in Philadelphia (Belantamab mafodotin)

Recruiting
  • Myeloma
  • Belantamab mafodotin
  • Philadelphia, Pennsylvania
    Abramson Cancer Center at University of Pennsylvania
Jun 13, 2022

Plasma Cell Myeloma Trial in Buffalo (Belantamab Mafodotin, Lenalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 5, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Birmingham, Alabama
  • +25 more
Dec 9, 2022

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Jul 23, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
Jul 27, 2022

Solid Tumor, Adult Trial in United States (IO-202, IO-202 + pembrolizumab combination therapy, RP2D of IO-202 + pembrolizumab

Not yet recruiting
  • Solid Tumor, Adult
  • IO-202
  • +2 more
  • Los Angeles, California
  • +3 more
Mar 25, 2022

Relapsed/Refractory Multiple Myeloma Trial in Australia, United States (ISB 1442 SC injection escalating doses, ISB 1442 SC

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 1442 SC injection escalating doses
  • ISB 1442 SC injection at RP2D
  • New York, New York
  • +5 more
Jun 17, 2022

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)

Recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Belantamab Mafodotin
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 10, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • New Port Richey, Florida
  • +94 more
Nov 30, 2022

Multiple Myeloma Trial (CM336_group 1, CM336_group 2a, CM336_group 2b)

Not yet recruiting
  • Multiple Myeloma
  • CM336_group 1
  • +14 more
  • (no location specified)
Mar 18, 2022

Plasma Cell Myeloma Trial in Atlanta (Belantamab Mafodotin, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Belantamab Mafodotin
  • +2 more
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
Jul 21, 2022

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Daratumumab, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Yuma, Arizona
  • +150 more
Dec 9, 2022

Multiple Myeloma Trial in Spain, United States (BB2121, CC-220, BMS-986405)

Recruiting
  • Multiple Myeloma
  • BB2121
  • +2 more
  • Birmingham, Alabama
  • +33 more
Jan 26, 2023

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Tucson, Arizona
  • +131 more
Jul 1, 2022

Multiple Myeloma Trial in Canada, United Kingdom, United States (GSK2857916)

Completed
Has Results
  • Multiple Myeloma
  • Boston, Massachusetts
  • +8 more
Jul 29, 2020

Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone))

Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Pom/dex (Pomalidomide plus low dose Dexamethasone)
  • Tucson, Arizona
  • +163 more
Feb 25, 2022

Multiple Myeloma Trial in Aichi, Okayama, Tokyo (Belantamab mafodotin, Bortezomib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Aichi, Japan
  • +3 more
Feb 8, 2022

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 24, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)

Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Los Angeles, California
  • +1 more
Aug 19, 2022

Advanced Malignant Solid Tumor, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +28 more
  • Conroe, Texas
  • +4 more
Dec 5, 2022

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (JNJ-79635322)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Edegem, Belgium
  • +16 more
Jan 27, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Multiple Myeloma, Refractory Trial in Washington, Hackensack, Neptune (Pembrolizumab, Belantamab mafodotin, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma, Refractory
  • Washington, District of Columbia
  • +2 more
Aug 5, 2022